Premium
P2‐062: Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease?
Author(s) -
Lista Simone,
Cavedo Enrica,
Zetterberg Henrik,
Dubois Bruno,
Epelbaum Stéphane,
Lamari Foudil,
Blennow Kaj,
Hampel Harald
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.599
Subject(s) - neurogranin , cerebrospinal fluid , hippocampus , medicine , dementia , white matter , hippocampal formation , biomarker , atrophy , neuroscience , psychology , endocrinology , pathology , magnetic resonance imaging , chemistry , disease , biochemistry , protein kinase c , radiology , enzyme
January-29-2015), CSF Ng levels analyses are ongoing and are anticipated to be completed on April 2015. The expected results are: (1) the presence of elevated CSFNg levels in AD dementia and prodromal AD, in line with previous studies, and (2) a significant association between CSF Ng levels and HV as well as brain WM volume in AD dementia and prodromal AD. Conclusions: The supposed correlation of increased CSF Ng levels with hippocampal atrophy and decreased WM volume might support the existence of an ongoing in vivo synaptic degeneration process. P2-063 Ab40 AND Ab42 LEVELS IN PLASMA: COMPARISON OF ENZYME-LINKED IMMUNOSORBENTASSAY (ELISA) WITH MULTIPLEX TECHNOLOGY Pankaj D. Mehta, Henrik Zetterberg, Kaj Blennow, Mony DeLeon, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M€olndal, Sweden; Clinical Neurochemistry Laboratory/ Sahlgrenska University Hospital, Gothenburg, Sweden; New York University, New York, NY, USA. Contact e-mail: pdmehtaphd@gmail.com Background:Wehypothesized that the differences in plasmaAb levels that predict dementia are due to variation in specificity and affinity of antibodies to Ab40 or Ab42 used in different assays. There is a continuing interest in themeasurement of plasmaAb40orAb42 levels in a longitudinal study of aging and Alzheimer disease (AD). However, the literature on plasma Ab levels in AD is inconsistent. Investigators speculated that one of the reasons for conflicting data is due to variation in antibodies used in different assays. However, no data is available on the measurement of plasma Ab levels using the same pool of samples in ELISA and multiplex assay. Methods:We examined 64 plasma samples in NY, using high affinity rabbit monoclonal (RabmAb) and polyclonal (RabpAb) antibodies to Ab40, and Ab42, respectively, in sandwich chemofluorescent ELISA. The same samples were examined using plasma Ab multiplex assay (INNO-BIA, Innogenetics) in Sweden. The data were compared with each constituent using Kruskal-Wallis ANOVA. Results: There was a significant correlation between Ab40 levels measured by RabmAb to Ab40 and RabpAb to Ab40 in ELISA (r 1⁄4.96; p<.001). There was no relationship between the levels measured by multiplex assay and RabmAb to Ab40 (r 1⁄4.21; p<.089), but borderline significance with RabpAb to Ab40 (r 1⁄4.24; p<.05). There was a significant correlationbetweenAb42 levelsmeasuredbyRabmAb toAb42andRabpAb toAb42 in ELISA (r1⁄4.97; p<.001).However, themultiplex data showed no correlation with RabmAb to Ab42 (r 1⁄4 -.078; p<.53) or RabpAb to Ab42 (r 1⁄4-.05; p<.69). Conclusions: The lack of correlation on plasmaAb levels in two assays is due to differences inaffinity and specificity of mouse and rabbit antibodies to Ab. Longitudinalmeasurements of plasmaAb levels in agingwill determine the diagnostic value of different antibodies. Study Supported by: New York State, Office of the People with Developmental Disabilities. P2-064 COGNITIVE IMPAIRMENT IN LEWY BODY DISEASE IS CORRELATEDWITH LEVELS OF CSF